(Q47994905)

7 February 2018

meta-analysis

0 references

title

Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials (English)

1 reference

7 February 2018

author name string

Fausto Petrelli

1

1 reference

7 February 2018

Andrea Coinu

2

1 reference

7 February 2018

Mary Cabiddu

3

1 reference

7 February 2018

Mara Ghilardi

4

1 reference

7 February 2018

Veronica Lonati

5

1 reference

7 February 2018

Sandro Barni

6

1 reference

7 February 2018

language of work or name

English

0 references

publication date

17 July 2013

1 reference

7 February 2018

Breast Cancer Research and Treatment

published in

1 reference

7 February 2018

volume

140

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

233-240

1 reference

7 February 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Differences in the receptor status between primary and recurrent breast cancer--the frequency of and the reasons for discordance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2629-4

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/S0140-6736(11)60993-8

Identifiers

DOI

10.1007/S10549-013-2629-4

1 reference

7 February 2018

1 reference

7 February 2018